世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

北米セルライト治療市場 2023-2030

北米セルライト治療市場 2023-2030


NORTH AMERICA CELLULITE TREATMENT MARKET 2023-2030

市場の展望 Triton Market Researchのレポートによると、北米のセルライト治療市場は、2023年から2030年の予測期間において、年平均成長率9.58%で推移するとされています。同地域では、カナダと米国が計られてい... もっと見る

　

　

出版社 出版年月 電子版価格 納期 ページ数 言語
Triton Market Research
トリトンマーケットリサーチ 		2023年5月2日 US$1,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		3-5営業日程度 116 英語

　

サマリー

市場の展望
Triton Market Researchのレポートによると、北米のセルライト治療市場は、2023年から2030年の予測期間において、年平均成長率9.58%で推移するとされています。同地域では、カナダと米国が計られています。
カナダでは、肥満の有病率の高さが市場成長の原動力となることが予想されます。推定によると、不健康なライフスタイルの選択により、肥満と診断される人の数は増加すると予想されます。このため、外見を美しくするための美容整形に対する需要がさらに高まると考えられます。さらに、老年人口の増加も、セルライト除去などの美容施術の需要を高めています。この点で、非侵襲的かつ低侵襲的な治療法は、セルライト治療市場の拡大を大きく後押ししています。
同様に、肥満率の高さから、米国ではさまざまな治療法を選択せざるを得ない状況になっています。低侵襲な施術が可能なため、セルライト治療を選択する患者数が大幅に増加しました。したがって、美意識の高まりと先進的な治療法が、米国におけるセルライト治療市場の全体的な範囲と成長を拡大させているのです。

競争展望
セルライト治療市場の既存企業は、AbbVie Inc、Bausch Health Companies Inc、Johnson & Johnson、Galderma SA、Endo International Plcで構成されています。


ページTOPに戻る


目次

TABLE OF CONTENTS
1. NORTH AMERICA CELLULITE TREATMENT MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. PARENT MARKET ANALYSIS
2.2. IMPACT ANALYSIS ON THE CELLULITE TREATMENT MARKET
2.2.1. COVID-19 IMPACT ON THE CELLULITE TREATMENT MARKET
2.2.2. UKRAINE-RUSSIA WAR IMPACT ON THE CELLULITE TREATMENT MARKET
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. MARKET MATURITY ANALYSIS
2.5. INDUSTRY COMPONENTS
2.5.1. RESEARCH AND DEVELOPMENT
2.5.2. MANUFACTURING OF PRODUCT
2.5.3. DISTRIBUTION
2.5.4. POST-SALES MONITORING
2.6. REGULATORY FRAMEWORK
2.7. KEY BUYING IMPACT ANALYSIS
2.7.1. PRICE
2.7.2. BRAND NAME
2.7.3. USABILITY
2.8. KEY MARKET STRATEGIES
2.8.1. COLLABORATIONS
2.8.2. PRODUCT LAUNCHES
2.8.3. MERGERS & ACQUISITIONS
2.8.4. BUSINESS DIVESTITURES & EXPANSIONS
2.9. MARKET DRIVERS
2.9.1. GROWING PREVALENCE OF OBESITY
2.9.2. RAPIDLY GROWING MEDICAL TOURISM SECTOR
2.9.3. RISING DEMAND FOR AESTHETIC PROCEDURES
2.10. MARKET CHALLENGES
2.10.1. LACK OF KNOWLEDGE REGARDING CELLULITE TREATMENT
2.10.2. HIGH PRICE OF ADVANCED CELLULITE TREATMENT
2.10.3. RISKS ASSOCIATED POST-TREATMENT
2.11. MARKET OPPORTUNITIES
2.11.1. RISING BEAUTY CONSCIOUSNESS
2.11.2. INCREASING TREND OF ANTI-CELLULITE MASSAGE
2.11.3. GROWING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES
2.11.4. RISING POPULARITY OF RADIOFREQUENCY THERAPY FOR CELLULITE TREATMENT
2.11.5. ADVANCEMENTS IN TECHNOLOGIES AND NEW PRODUCT LAUNCHES
2.12. ANALYST PERSPECTIVE
3. NORTH AMERICA CELLULITE TREATMENT MARKET – BY CELLULITE TYPE
3.1. SOFT CELLULITE
3.2. HARD CELLULITE
3.3. EDEMATOUS CELLULITE
4. NORTH AMERICA CELLULITE TREATMENT MARKET – BY PROCEDURE TYPE
4.1. NON-INVASIVE
4.2. MINIMALLY INVASIVE
4.3. TOPICAL
5. NORTH AMERICA CELLULITE TREATMENT MARKET – BY END-USER
5.1. HOSPITALS
5.2. CLINICS AND BEAUTY CENTERS
5.3. OTHER END-USERS
6. NORTH AMERICA CELLULITE TREATMENT MARKET – BY COUNTRY OUTLOOK
6.1. COUNTRY ANALYSIS
6.1.1. UNITED STATES
6.1.1.1. UNITED STATES CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.2. CANADA
6.1.2.1. CANADA CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
7. COMPETITIVE LANDSCAPE
7.1. JOHNSON & JOHNSON
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY STRENGTHS
7.1.4. KEY CHALLENGES
7.2. ABBVIE INC
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY STRENGTHS
7.2.4. KEY CHALLENGES
7.3. BAUSCH HEALTH COMPANIES INC
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY STRENGTHS
7.3.4. KEY CHALLENGES
7.4. CUTERA INC
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY STRENGTHS
7.4.4. KEY CHALLENGES
7.5. INCELER MEDIKAL
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY STRENGTHS
7.5.4. KEY CHALLENGES
7.6. ZIMMER MEDIZINSYSTEME GMBH
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY STRENGTHS
7.6.4. KEY CHALLENGES
7.7. GALDERMA SA
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY STRENGTHS
7.7.4. KEY CHALLENGES
7.8. SIENTRA INC
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY STRENGTHS
7.8.4. KEY CHALLENGES
7.9. ENDO INTERNATIONAL PLC
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY STRENGTHS
7.9.4. KEY CHALLENGES
7.10. CANDELA MEDICAL CORPORATION
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY STRENGTHS
7.10.4. KEY CHALLENGES
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.1.1. OBJECTIVES OF STUDY
8.1.2. SCOPE OF STUDY
8.2. SOURCES OF DATA
8.2.1. PRIMARY DATA SOURCES
8.2.2. SECONDARY DATA SOURCES
8.3. RESEARCH METHODOLOGY
8.3.1. EVALUATION OF THE PROPOSED MARKET
8.3.2. IDENTIFICATION OF DATA SOURCES
8.3.3. ASSESSMENT OF MARKET DETERMINANTS
8.3.4. DATA COLLECTION
8.3.5. DATA VALIDATION & ANALYSIS


TABLE LIST
TABLE 1: NORTH AMERICA CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 7: NORTH AMERICA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2023-2030 (IN $ MILLION)
TABLE 8: NORTH AMERICA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2023-2030 (IN $ MILLION)
TABLE 9: NORTH AMERICA CELLULITE TREATMENT MARKET, BY END-USER, 2023-2030 (IN $ MILLION)
TABLE 10: NORTH AMERICA CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

FIGURE LIST
FIGURE 1: MARKET MATURITY ANALYSIS
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: KEY BUYING IMPACT ANALYSIS
FIGURE 4: NORTH AMERICA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2022 & 2030 (IN %)
FIGURE 5: NORTH AMERICA CELLULITE TREATMENT MARKET, BY SOFT CELLULITE, 2023-2030 (IN $ MILLION)
FIGURE 6: NORTH AMERICA CELLULITE TREATMENT MARKET, BY HARD CELLULITE, 2023-2030 (IN $ MILLION)
FIGURE 7: NORTH AMERICA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2022 & 2030 (IN %)
FIGURE 8: NORTH AMERICA CELLULITE TREATMENT MARKET, BY NON-INVASIVE, 2023-2030 (IN $ MILLION)
FIGURE 9: NORTH AMERICA CELLULITE TREATMENT MARKET, BY MINIMALLY INVASIVE, 2023-2030 (IN $ MILLION)
FIGURE 10: NORTH AMERICA CELLULITE TREATMENT MARKET, BY TOPICAL, 2023-2030 (IN $ MILLION)
FIGURE 11: NORTH AMERICA CELLULITE TREATMENT MARKET, BY END-USER, 2022 & 2030 (IN %)
FIGURE 12: NORTH AMERICA CELLULITE TREATMENT MARKET, BY HOSPITALS, 2023-2030 (IN $ MILLION)
FIGURE 13: NORTH AMERICA CELLULITE TREATMENT MARKET, BY CLINICS AND BEAUTY CENTERS, 2023-2030 (IN $ MILLION)
FIGURE 14: NORTH AMERICA CELLULITE TREATMENT MARKET, BY OTHER END-USERS, 2023-2030 (IN $ MILLION)
FIGURE 15: NORTH AMERICA CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2022 & 2030 (IN %)
FIGURE 16: UNITED STATES CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 17: CANADA CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)

ページTOPに戻る



図表リスト

TABLE LIST
TABLE 1: NORTH AMERICA CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 7: NORTH AMERICA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2023-2030 (IN $ MILLION)
TABLE 8: NORTH AMERICA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2023-2030 (IN $ MILLION)
TABLE 9: NORTH AMERICA CELLULITE TREATMENT MARKET, BY END-USER, 2023-2030 (IN $ MILLION)
TABLE 10: NORTH AMERICA CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

　

ページTOPに戻る


　

Summary

MARKET OUTLOOK
Triton Market Research’s report reckons that the cellulite treatment market in North America is set to advance with a compound annual growth rate of 9.58% over the forecasting years 2023-2030. Canada and the United States are gauged in the region.
The high prevalence of obesity is expected to drive the market’s growth in Canada. As per estimates, the number of people diagnosed with obesity is expected to rise owing to unhealthy lifestyle choices. This will further elevate the demand for cosmetic procedures to enhance appearance. Moreover, the increase in the geriatric population has also surged the demand for aesthetic treatments like cellulite reduction. In this regard, non-invasive and minimally invasive treatments have significantly backed the expansion of the cellulite treatment market.
Likewise, the high obesity rates have compelled people to opt for various treatments in the US. The availability of minimally invasive procedures has significantly increased the number of patients opting for cellulite treatments. Hence, the growing beauty consciousness and advanced treatments widen the overall scope and growth of the cellulite treatment market across the United States.

COMPETITIVE OUTLOOK
The established companies in the cellulite treatment market consist of AbbVie Inc, Bausch Health Companies Inc, Johnson & Johnson, Galderma SA, and Endo International Plc.



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1. NORTH AMERICA CELLULITE TREATMENT MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. PARENT MARKET ANALYSIS
2.2. IMPACT ANALYSIS ON THE CELLULITE TREATMENT MARKET
2.2.1. COVID-19 IMPACT ON THE CELLULITE TREATMENT MARKET
2.2.2. UKRAINE-RUSSIA WAR IMPACT ON THE CELLULITE TREATMENT MARKET
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. MARKET MATURITY ANALYSIS
2.5. INDUSTRY COMPONENTS
2.5.1. RESEARCH AND DEVELOPMENT
2.5.2. MANUFACTURING OF PRODUCT
2.5.3. DISTRIBUTION
2.5.4. POST-SALES MONITORING
2.6. REGULATORY FRAMEWORK
2.7. KEY BUYING IMPACT ANALYSIS
2.7.1. PRICE
2.7.2. BRAND NAME
2.7.3. USABILITY
2.8. KEY MARKET STRATEGIES
2.8.1. COLLABORATIONS
2.8.2. PRODUCT LAUNCHES
2.8.3. MERGERS & ACQUISITIONS
2.8.4. BUSINESS DIVESTITURES & EXPANSIONS
2.9. MARKET DRIVERS
2.9.1. GROWING PREVALENCE OF OBESITY
2.9.2. RAPIDLY GROWING MEDICAL TOURISM SECTOR
2.9.3. RISING DEMAND FOR AESTHETIC PROCEDURES
2.10. MARKET CHALLENGES
2.10.1. LACK OF KNOWLEDGE REGARDING CELLULITE TREATMENT
2.10.2. HIGH PRICE OF ADVANCED CELLULITE TREATMENT
2.10.3. RISKS ASSOCIATED POST-TREATMENT
2.11. MARKET OPPORTUNITIES
2.11.1. RISING BEAUTY CONSCIOUSNESS
2.11.2. INCREASING TREND OF ANTI-CELLULITE MASSAGE
2.11.3. GROWING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES
2.11.4. RISING POPULARITY OF RADIOFREQUENCY THERAPY FOR CELLULITE TREATMENT
2.11.5. ADVANCEMENTS IN TECHNOLOGIES AND NEW PRODUCT LAUNCHES
2.12. ANALYST PERSPECTIVE
3. NORTH AMERICA CELLULITE TREATMENT MARKET – BY CELLULITE TYPE
3.1. SOFT CELLULITE
3.2. HARD CELLULITE
3.3. EDEMATOUS CELLULITE
4. NORTH AMERICA CELLULITE TREATMENT MARKET – BY PROCEDURE TYPE
4.1. NON-INVASIVE
4.2. MINIMALLY INVASIVE
4.3. TOPICAL
5. NORTH AMERICA CELLULITE TREATMENT MARKET – BY END-USER
5.1. HOSPITALS
5.2. CLINICS AND BEAUTY CENTERS
5.3. OTHER END-USERS
6. NORTH AMERICA CELLULITE TREATMENT MARKET – BY COUNTRY OUTLOOK
6.1. COUNTRY ANALYSIS
6.1.1. UNITED STATES
6.1.1.1. UNITED STATES CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
6.1.2. CANADA
6.1.2.1. CANADA CELLULITE TREATMENT MARKET FORECAST & PROSPECTS
7. COMPETITIVE LANDSCAPE
7.1. JOHNSON & JOHNSON
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY STRENGTHS
7.1.4. KEY CHALLENGES
7.2. ABBVIE INC
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY STRENGTHS
7.2.4. KEY CHALLENGES
7.3. BAUSCH HEALTH COMPANIES INC
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY STRENGTHS
7.3.4. KEY CHALLENGES
7.4. CUTERA INC
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY STRENGTHS
7.4.4. KEY CHALLENGES
7.5. INCELER MEDIKAL
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY STRENGTHS
7.5.4. KEY CHALLENGES
7.6. ZIMMER MEDIZINSYSTEME GMBH
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY STRENGTHS
7.6.4. KEY CHALLENGES
7.7. GALDERMA SA
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY STRENGTHS
7.7.4. KEY CHALLENGES
7.8. SIENTRA INC
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY STRENGTHS
7.8.4. KEY CHALLENGES
7.9. ENDO INTERNATIONAL PLC
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY STRENGTHS
7.9.4. KEY CHALLENGES
7.10. CANDELA MEDICAL CORPORATION
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY STRENGTHS
7.10.4. KEY CHALLENGES
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.1.1. OBJECTIVES OF STUDY
8.1.2. SCOPE OF STUDY
8.2. SOURCES OF DATA
8.2.1. PRIMARY DATA SOURCES
8.2.2. SECONDARY DATA SOURCES
8.3. RESEARCH METHODOLOGY
8.3.1. EVALUATION OF THE PROPOSED MARKET
8.3.2. IDENTIFICATION OF DATA SOURCES
8.3.3. ASSESSMENT OF MARKET DETERMINANTS
8.3.4. DATA COLLECTION
8.3.5. DATA VALIDATION & ANALYSIS


TABLE LIST
TABLE 1: NORTH AMERICA CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 7: NORTH AMERICA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2023-2030 (IN $ MILLION)
TABLE 8: NORTH AMERICA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2023-2030 (IN $ MILLION)
TABLE 9: NORTH AMERICA CELLULITE TREATMENT MARKET, BY END-USER, 2023-2030 (IN $ MILLION)
TABLE 10: NORTH AMERICA CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

FIGURE LIST
FIGURE 1: MARKET MATURITY ANALYSIS
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: KEY BUYING IMPACT ANALYSIS
FIGURE 4: NORTH AMERICA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2022 & 2030 (IN %)
FIGURE 5: NORTH AMERICA CELLULITE TREATMENT MARKET, BY SOFT CELLULITE, 2023-2030 (IN $ MILLION)
FIGURE 6: NORTH AMERICA CELLULITE TREATMENT MARKET, BY HARD CELLULITE, 2023-2030 (IN $ MILLION)
FIGURE 7: NORTH AMERICA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2022 & 2030 (IN %)
FIGURE 8: NORTH AMERICA CELLULITE TREATMENT MARKET, BY NON-INVASIVE, 2023-2030 (IN $ MILLION)
FIGURE 9: NORTH AMERICA CELLULITE TREATMENT MARKET, BY MINIMALLY INVASIVE, 2023-2030 (IN $ MILLION)
FIGURE 10: NORTH AMERICA CELLULITE TREATMENT MARKET, BY TOPICAL, 2023-2030 (IN $ MILLION)
FIGURE 11: NORTH AMERICA CELLULITE TREATMENT MARKET, BY END-USER, 2022 & 2030 (IN %)
FIGURE 12: NORTH AMERICA CELLULITE TREATMENT MARKET, BY HOSPITALS, 2023-2030 (IN $ MILLION)
FIGURE 13: NORTH AMERICA CELLULITE TREATMENT MARKET, BY CLINICS AND BEAUTY CENTERS, 2023-2030 (IN $ MILLION)
FIGURE 14: NORTH AMERICA CELLULITE TREATMENT MARKET, BY OTHER END-USERS, 2023-2030 (IN $ MILLION)
FIGURE 15: NORTH AMERICA CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2022 & 2030 (IN %)
FIGURE 16: UNITED STATES CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)
FIGURE 17: CANADA CELLULITE TREATMENT MARKET 2023-2030 (IN $ MILLION)

ページTOPに戻る



List of Tables/Graphs

TABLE LIST
TABLE 1: NORTH AMERICA CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 7: NORTH AMERICA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2023-2030 (IN $ MILLION)
TABLE 8: NORTH AMERICA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2023-2030 (IN $ MILLION)
TABLE 9: NORTH AMERICA CELLULITE TREATMENT MARKET, BY END-USER, 2023-2030 (IN $ MILLION)
TABLE 10: NORTH AMERICA CELLULITE TREATMENT MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

Triton Market Research社の
Fatal error: Uncaught TypeError: Cannot access offset of type string on string in /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/templates_c/58b4bde6a9738f3389cd7dea7f4ef5c62fdc6c54_0.file.auto_report.tpl.php:571 Stack trace: #0 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_resource_base.php(123): content_68a805fa34b2e0_16717164() #1 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_compiled.php(114): Smarty_Template_Resource_Base->getRenderedTemplateCode() #2 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_template.php(216): Smarty_Template_Compiled->render() #3 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_template.php(385): Smarty_Internal_Template->render() #4 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/templates_c/f20300271f4eb0fb4a2cf788aaabb06be5646d19_0.file.frame-FULL.tpl.php(278): Smarty_Internal_Template->_subTemplateRender() #5 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_resource_base.php(123): content_68a805fa26a288_46622063() #6 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_compiled.php(114): Smarty_Template_Resource_Base->getRenderedTemplateCode() #7 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_template.php(216): Smarty_Template_Compiled->render() #8 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_templatebase.php(238): Smarty_Internal_Template->render() #9 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_templatebase.php(134): Smarty_Internal_TemplateBase->_execute() #10 /var/www/vhosts/dri.co.jp/httpdocs/auto/show_report.php(776): Smarty_Internal_TemplateBase->display() #11 {main} thrown in /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/templates_c/58b4bde6a9738f3389cd7dea7f4ef5c62fdc6c54_0.file.auto_report.tpl.php on line 571